Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 211

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer

Open access
Spratt, Daniel E., Zhang, Jingbin, Santiago-Jiménez, María, Dess, Robert T., Davis, John W., Den, Robert B., Dicker, Adam P., Kane, Christopher J., Pollack, Alan, Stoyanova, Radka, Abdollah, Firas, Ross, Ashley E., Cole, Adam, Uchio, Edward, Randall, Josh M., Nguyen, Hao, Zhao, Shuang G., Mehra, Rohit, Glass, Andrew G., Lam, Lucia L.C., Chelliserry, Jijumon, du Plessis, Marguerite, Choeurng, Voleak, Aranes, Maria, Kolisnik, Tyler, Margrave, Jennifer, Alter, Jason, Jordan, Jennifer, Buerki, Christine, Yousefi, Kasra, Haddad, Zaid, Davicioni, Elai, Trabulsi, Edouard J., Loeb, Stacy, Tewari, Ashutosh, Carroll, Peter R., Weinmann, Sheila, Schaeffer, Edward M., Klein, Eric A., Karnes, R. Jeffrey, Feng, Felix Y., Nguyen, Paul L. · 2018 · Journal of Clinical Oncology

Abstract

Purpose: It is clinically challenging to integrate genomic-classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostate cancer, which are founded in the framework of risk groups. We aimed to develop a novel clinical-genomic risk grouping system that can readily be incorporated into treatment guidelines for localized prostate cancer. Materials and Methods: Two multicenter cohorts (n = 991) were used for training and validation of the clinical-genomic risk groups, and two additional cohorts (n = 5,937) were used for reclassification analyses. Competing risks analysis was used to estimate the risk of distant metastasis. Time-dependent c-indices were constructed to compare clinicopathologic risk models with the clinical-genomic risk groups. Results: With a median follow-up of 8 years for patients in the training cohort, 10-year distant metastasis rates for National Comprehensive Cancer Network (NCCN) low, favorable-intermediate, unfavorable-intermediate, and high-risk were 7.3%, 9.2%, 38.0%, and 39.5%, respectively. In contrast, the three-tier clinical-genomic risk groups had 10-year distant metastasis rates of 3.5%, 29.4%, and 54.6%, for low-, intermediate-, and high-risk, respectively, which were consistent in the validation cohort (0%, 25.9%, and 55.2%, respectively). C-indices for the clinical-genomic risk grouping system (0.84; 95% CI, 0.61 to 0.93) were improved over NCCN (0.73; 95% CI, 0.60 to 0.86) and Cancer of the Prostate Risk Assessment (0.74; 95% CI, 0.65 to 0.84), and 30% of patients using NCCN low/intermediate/high would be reclassified by the new three-tier system and 67% of patients would be reclassified from NCCN six-tier (very-low– to very-high–risk) by the new six-tier system. Conclusion: A commercially available genomic classifier in combination with standard clinicopathologic variables can generate a simple-to-use clinical-genomic risk grouping that more accurately identifies patients at low, intermediate, and high risk for metastasis and can be easily incorporated into current guidelines to better risk-stratify patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.74.2940

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 211

Metadata

Authors
Spratt, D. E., Zhang, J., Santiago-Jiménez, M., Dess, R. T., Davis, J. W., Den, R. B., Dicker, A. P., Kane, C. J., Pollack, A., Stoyanova, R., Abdollah, F., Ross, A. E., Cole, A., Uchio, E., Randall, J. M., Nguyen, H., Zhao, S. G., Mehra, R., Glass, A. G., Lam, L. L. C., Chelliserry, J., du Plessis, M., Choeurng, V., Aranes, M., Kolisnik, T., Margrave, J., Alter, J., Jordan, J., Buerki, C., Yousefi, K., Haddad, Z., Davicioni, E., Trabulsi, E. J., Loeb, S., Tewari, A., Carroll, P. R., Weinmann, S., Schaeffer, E. M., Klein, E. A., Karnes, R. J., Feng, F. Y., & Nguyen, P. L.
Venue
Journal of Clinical Oncology
Published
2018-02-20
Volume
36
Issue
6
Pages
581-590
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2769578203
Cited by
211
References
2
FWCI
18.22
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.2017.74.2940
The paper
Spratt, D. E., Zhang, J., Santiago-Jiménez, M., Dess, R. T., Davis, J. W., Den, R. B., Dicker, A. P., Kane, C. J., Pollack, A., Stoyanova, R., Abdollah, F., Ross, A. E., Cole, A., Uchio, E., Randall, J. M., Nguyen, H., Zhao, S. G., Mehra, R., Glass, A. G., . . . Nguyen, P. L. (2018). Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.74.2940

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.